Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)

Completed · Not applicable

Conditions studied: Leukoplakia, Hairy, HIV Infections

In brief

To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr virus (EBV) related hairy leukoplakia (HL). To determine the long-term safety of acyclovir in the AIDS-related complex (ARC) patient with HL. To monitor the progression of HIV disease in the HL patient and compare to existing historical control data.

Key facts

Study ID

NCT00002026

Run by

Glaxo Wellcome

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Concurrent Medication:
• Allowed:
• Topical antifungal therapy.
• Patient must have:
• Newly diagnosed clinical and histological hairy leukoplakia.
• Positive HIV antibody by licensed ELISA or Western blot.

You may not qualify if…

• Co-existing Condition:
• Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded.
• Concurrent Medication:
• Excluded within 2 weeks of study entry:
• Systemic antifungal treatment.
• Excluded within 6 weeks of study entry:
• Immunomodulators.
• Systemic antiviral treatment.
• Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded.
• Prior Medication:
• Excluded within 2 weeks of study entry:
• Systemic antifungal.
• Excluded within 6 weeks of study entry:
• Immunomodulators.
• Systemic antiviral treatment.
• Excluded within 8 weeks of study entry:
• Zidovudine (AZT) or other antiretroviral therapy.

Where it is running

• Univ of Southern California / LA County USC Med Ctr — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.